IntroDuctIon
Development of multidentate small-molecule ligands that can bind to multiple sites on proteins is an important and evolving area for the discovery of potent therapeutic agents. In the case of protein tyrosine phosphatases (PTPs), the active sites often share high sequence homology and it is generally thought that inhibitors targeting only the catalytic pockets may lack selectivity. However, crystal structures of PTPs show that protein surface topology proximal to the active sites may provide features that are unique to each PTP and that residues in these peripheral sites may be important for unique substrate recognition for each PTPs [1] [2] [3] [4] [5] [6] . Therefore, multidentate agents targeting the active sites as well as sites outside the catalytic pocket may show enhanced selectivity. In addition, tethering of components to provide multidentate ligands that simultaneously bind both within the active site and in peripheral areas outside the catalytic pocket should lead to inhibitors that are more potent than those that bind only within the active catalytic pocket. Protein-protein interactions (PPIs) have also been considered to be difficult targets because of the extended nature of their contact surfaces. However, X-ray studies often show the presence of discrete pockets within these contact areas, which form by the plasticity of the interface upon binding with different ligands [7] [8] [9] . This feature allows for the development of high-affinity multidentate ligands that can target these interface subpockets.
Ligand tethering strategies are widely used for the expedited development of multivalent agents. One approach uses Cu(I)-catalyzed 'click chemistry' to accelerate the synthesis and discovery of drug-like molecules targeting enzymes 10 . The term click chemistry was introduced by Sharpless 11 to describe a class of reactions that includes the Huisgen 1,3-dipolar cycloaddition of alkynes to azides to form 1,4-disubsituted-1,2,3-triazoles 12 . These reactions are highly versatile because of the mild reaction conditions required and good chemoselectivity. To this date, this form of click chemistry has been successfully used in drug discovery, where it has been used to assemble and generate a large number of small-molecule inhibitors and to successfully screen them against various enzymes [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . However, a limitation associated with this approach is that the azide-containing starting materials may either be expensive or of limited commercial availability, thereby requiring their high-throughput synthesis [14] [15] [16] [17] [18] [19] 24 . In addition, the reactions typically require catalysis by Cu(I) 13, [25] [26] [27] [28] , which is either dissolved in organic solvents or prepared in situ from the reduction of Cu(II) using ascorbic acid 29, 30 in mixtures of H 2 O and tert-butanol. This can necessitate purification of the reaction products before biological evaluation. The azide-alkyne click chemistry, although easy to execute, results in reaction products with moderate yields (approximately 30-80%) 13, 15, 18 . It can also be limited by the availability of azide starting materials and a requirement for product purification. This can present significant limitation for the rapid generation of multivalent inhibitors in sufficient purity for direct biological evaluation. Oxime-based ligation provides an alternate form of click chemistry that does not require high cost or synthesis of library-building blocks, and which results in the generation of reaction products with sufficient purity and biocompatibility for direct biological evaluation. This results in expedited tethering and in situ screening of multidentate ligands.
We have recently used an alternate methodology that uses an oxime-based tethering approach for the rapid generation and screening of multivalent ligands without the need for purification. A distinctive feature of this type of ligation is its use of aminooxycontaining handles that are reacted with aldehydes to form stable oxime bonds (Fig. 1) . Oxime tethering is an attractive and efficient approach that uses inexpensive commercially available aldehyde starting materials. Oxime bond formation does not require high reaction temperatures, it can be performed under aqueous conditions, and it is chemospecific and sufficiently stable to allow for initial biological evaluation without purification. Each tethering reaction is carried out by incubating an aminoxy-containing platform with alkyl and aryl aldehyde fragments in the presence of acetic acid in a molar ratio of 1:1:2-5. Precalculated molar concentrations of the reactants allow serial dilution of final oxime products. Reactions are complete overnight at room temperature in typically 90% or greater yields as shown by random HPLC analysis for both alkyl and aryl tethering. The oxime bond is very stable and its cleavage occurs only under acidic reflux condition 31 . Thus, oxime products in DMSO solutions can be stored indefinitely at 2-8 °C (small molecules) and − 20 °C (peptidic oximes). The reaction products can be transferred without purification to Titertubes or 96-well microplates and diluted for evaluation against biological targets at different ligand concentrations. We have applied this rapid oxime ligation approach to the development of nonpeptidic multidentate PTPs inhibitors, where the binding interactions span regions both inside and outside of the conserved catalytic pocket [32] [33] [34] . We have also used this method to optimize peptide antagonist targeting interactions between Tsg101 and HIV-1 Gag in an effort to develop virus-budding inhibitors [35] [36] [37] . Therefore, the discovery of potent inhibitors through oxime library diversification is applicable to targets that have multiple binding pockets (catalytic and secondary pockets/peripheral sites), such as kinases and phosphatases, and to enzymes with extended sites, such as proteases. The approach is also applicable for generating oxime-based peptides that can serve as effective binding antagonists inhibiting PPIs.
General approach
The general steps taken to develop enzyme inhibitors using oxime library diversification are: (i) identification of both core and peripheral sites of the enzyme; (ii) identification of lead compounds that interact with the active site and the strategic introduction of aminooxy handles; (iii) oxime-based tethering by reacting the library of aldehydes with the aminooxy platform; and (iv) screening against a target enzyme for the identification of potential inhibitors.
Nonpeptidic multidentate PTP inhibitors
PTPs are a class of enzymes that reverse the actions of protein tyrosine kinases. They exert important regulatory functions, with deregulation having been linked to a number of diseases, including cancer, diabetes and osteoporosis [38] [39] [40] . Our laboratory The position where the aminooxy residue is inserted is indicated in bold (see We have recently reported the development of an aminooxy inhibitor platform 1 (Fig. 2a) that was derived from substrate screening 34 . The crystal structure of 1 in complex with YopH (PDB: 2Y2F, Fig. 2a) showed that the difluoromethyl phosphonate mimetic of 1 is tightly bound within the catalytic pocket through hydrogen bonds to the signature motif phosphate-binding loop 'P-loop' 41 and the invariant tryptophan, proline, aspartic acidloop 'WPD-loop' 42 . These interactions are similar to those involved by a native phosphate group. A crucial feature revealed by the structure involved the conserved water molecule (Wa43), which lies outside the catalytic pocket and functions as a hydrogen bonding bridge between the aminooxy group and D231. This suggested that the platform could be used for inhibitor design by oxime tethering with one part of the molecule binding to a site outside the catalytic cleft. The R groups from RCHO-building block can be easily assembled onto the aminooxy functionality via oxime bond formation to yield additional binding interactions with residues at peripheral sites.
The furanyl-based oxime 2 ( Fig. 2b) was strategically designed using ICM Chemist Pro software. Docking of the inhibitor onto YopH showed that in addition to oxime nitrogen atom, the furanyl oxygen hydrogen bonds with the D231 residue through the Wa43 molecule. On the basis of these results a focused furanyloxime library was synthesized by a parallel reaction of the aminooxy platform with furanyl aldehydes. Without purification, the resultant products were directly screened in an in vitro YopH assay. Inhibitory potencies (IC 50 values) were obtained spectrophotometrically using p-nitrophenylphosphate (pNPP) as the chromogenic substrate. Inhibitor 3 was found to have IC 50 value with a sixfold improvement relative to the parent oxime 2. In silico docking studies of inhibitor 3 showed multiple interactions of the carboxyl group with R230 and D231.
Peptide antagonists targeting interactions between human Tsg101 and HIV-1 Gag
A second example of our oxime-based ligation concerns our development of PPI antagonists directed against human Tsg101. Tsg101 is a subunit protein of mammalian endosomal sorting complexes required for transport-I related to the cellular vascular protein-sorting pathway 43 . In HIV-infected cells, viral release requires direct interaction of the ubiquitin E2 variant (UEV) domain of Tsg101 with HIV-1 Gag protein 44 . Structural analysis of the Tsg101-Gag complex has shown the importance of a highly conserved motif Pro-Thr-Ala-Pro (PTAP), which is a proline-rich sequence located in the Gag p6 region. Interaction of Tsg101 with Gag p6 represents a target for the development of competitive PPI inhibitors as potential new antiviral therapies [45] [46] [47] [48] . The nonamer PTAP-containing sequence 'P 1 E 2 P 3 T 4 A 5 P 6 P 7 E 8 E 9 ' has been shown by NMR solution studies 46, 49 to bind to Tsg101 with modest affinity (K d = 50-60 µM) 36 . Based on the lead nonamer sequence we synthesized a series of Tsg101-binding peptides using post-solid-phase oxime formation that involved the reaction of a set of aminooxy-containing peptides with libraries of aldehydes [35] [36] [37] . The aminooxy-containing amino acids 4-7 shown in Table 1 (Fig. 1b and (SPPS) 50,51 from 4-7 and other commercially available peptides and purified using HPLC. The resulting purified aminooxy-containing peptides 8a-l were then subjected to oxime-based library diversification by reacting each peptide with a series of commercially available aldehydes a-l (Fig. 3) . The peptide oximes (>90% pure) were used directly in binding studies with Tsg101. As a result of this study, the 3,4-dimethoxybenzyl oxime-containing peptide 9 was found to show 15-to 20-fold binding enhancement (K d = 3.3 µM, Fig. 4) as compared with the wild-type parent peptide (K d = 50-60 µM). The protein interactions of the 3,4-dimethoxybenzyl groups in the crystal structure 37 allowed the identification of a new binding region that most probably would not have been revealed using coded amino acids.
Overview of the procedure
The current protocol describes the synthesis of aminooxy-building blocks 1 for YopH ( Fig. 5 strategically provide reaction products in appropriate molar concentrations for dilution before biological screening. The molar concentration of catalytic acetic acid depends on the nature of the aminooxy platform, where 2 and 5 equivalents of acetic acid have been used for smallmolecule and peptidic aminooxys functionality, respectively. A parallel independent assay of one more replicate is performed for each compound 3 and 9. Protocols for the screening of oxime inhibitors against YopH in a 96-well plate and for the screening of oxime inhibitors against Tsg101 (Fig. 9 ) are shown in Boxes 1 and 2, respectively. The identified inhibitors can then be synthesized on a large scale, purified and reexamined against their intended targets to verify the reproducibility of the initially observed inhibition. The rapid generation and in situ screening of oxime-based tethered constructs described herein can be applied to the rapid design and development of other enzyme or PPI-targeted multidentate inhibitors. 
MaterIals
REAGENTS  crItIcal All procedures should be conducted in a fume hood. The solid and liquid waste products generated should be disposed of appropriately, as defined locally. The solvents used in the reactions should be of the highest quality available. When an anhydrous solvent is to be used, this is indicated clearly in the PROCEDURE. Anhydrous solvents are dried according to the methods indicated or are purchased in anhydrous form as indicated. The solvents used in the extraction and workup phases should be of reagent quality or better. All of the reagents in the REAGENT SETUP should be freshly prepared. ! cautIon Wear gloves and goggles and work in a fume hood, as some of these chemicals are especially dangerous as indicated below. • (continued) EQUIPMENT SETUP HPLC Final aminooxy products (1 and 8d) and the identified potent inhibitors (3 and 9) can be purified by HPLC using a Waters Prep-LC 4000 system and Phenomenex Gemini 10-µm, 110-Å C18 columns (250 × 21.20 mm 2 , 10 µm) at a flow rate of 10 ml min − 1 (preparative HPLC) with a mobile phase of A = 0.1% aqueous TFA and B = 0.1% TFA in acetonitrile. In our laboratory, typical gradients are from 10% B to 100% B over 40 min for 1 and 3 (UV detection at 210, 254 and 280 nm); and 0% B to 100% B over 30 min followed by 100% B for 10 min for 8d and 9 (UV detection at 225, 254 and 280 nm). The purity of final tested products (3 and 9) can be determined by analytical HPLC using a Waters Prep-LC 4000 system and Phenomenex Gemini 5-µm, 110-Å C18 columns (250-4.60 mm, 5 µm) at a flow rate of 1 ml min − 1 with a mobile phase of A = 0.1% aqueous TFA and B = 0.1% TFA in acetonitrile. In our laboratory, typical gradients are from 10% B to 100% B over 40 min for 3 (UV detection at 210, 254 and 280 nm); and 5% B to 100% B over 30 min followed by 100% B for 10 min for 9 (UV detection at 225, 254 and 280 nm). All concentrations are expressed in vol/vol. SPPS column It is important to perform SPPS (Steps 41-74) in Pierce disposable columns with agitation using a Barnstead/Thermolyne Labquake tube shaker.
Box 2 | (continued)
12| The fluorescence anisotropy data are plotted against the concentration of Tsg101 using MATLAB software and the binding curves fit using the following equation:
where 5 ) . ! cautIon The reaction is exothermic; add dropwise over 30 min. Cool to room temperature and stir the reaction mixture for 3 h.
2|
Add CuBr (2.79 g, 19.4 mmol) in one portion, and then stir the mixture for 30 min at room temperature.
3|
Add a solution of bromo-3-iodobenzene (2.00 g, 7.1 mmol) in 1 ml of DMF dropwise. Stir for 24 h at room temperature.
4| Add H 2 O (10 ml) and diethylether (10 ml), and pass the mixture through Celite. Separate the layers by using a separatory funnel and extract the aqueous layer with diethylether (3 × 20 ml).
5| Dry the organic extracts over MgSO 4 , filter and remove the solvent. 
16| Remove solvent.
17| Dissolve the resulting crude material in H 2 O (2 ml) and methanol (2 ml) and filter using a syringe filter.
18|
Purify by preparative HPLC using the method as described in the EQUIPMENT SETUP (retention time 15.598 min). Lyophilization provides 1 as a white solid.  pause poInt The resultant aminooxy 1 can be stored for extended period at − 20 °C. synthesis of platform 18 • tIMInG 8 d 19| Add CbzCl (11.8 ml, 84.8 mmol) slowly to a mixture of (R)-4-hydroxy-L-proline (10.0 g, 76.0 mmol) and NaHCO 3 (12.8 g, 0.15 mol) in H 2 O (150 ml) and THF (150 ml) at 0 °C. Warm the reaction mixture to room temperature and stir for 12 h (refer to Fig. 6 ).
20|
Remove the organic solvent and extract the aqueous phase with diethylether (2 × 100 ml).
21|
Discard the diethylether layer and acidify the aqueous phase to pH 2-3 by the addition of 1 N HCl and extract with ethyl acetate (3 × 100 ml). Wash the combined ethyl acetate extracts with brine (50 ml), dry over Na 2 SO 4 and evaporate to provide Cbz-protected product. 
22|
Stir a portion of the resultant material (17.5 g, 66.0 mmol), benzyl bromide (8.7 ml, 73.0 mmol) and triethylamine
23|
Dilute with ethyl acetate (200 ml) and wash with H 2 O (2 × 50 ml) and brine (50 ml). Dry over Na 2 SO 4 , filter, remove the solvent and purify by silica gel column chromatography (2:1 hexanes/ethyl acetate) to give (2S,4R)-dibenzyl 4-hydroxypyrrolidine-1,2-dicarboxylate 13 (30.5 cm × 5.0 cm (effective length × inside diameter)(CG1189-19); TLC (hexanes/ethyl acetate 1:1 (vol/vol)) R f = 0.30).
24|
Add DEAD (7.06 g, 26.9 mmol) slowly to a solution of 13 (4.30 g, 12.2 mmol), p-nitrobenzoic acid (4.09 g, 24. 46 mmol) and triphenylphosphine (7.06 g, 26.9 mmol) in THF (150 ml) at 0 °C. Warm the mixture to room temperature and stir for 12 h. 35| Stir a mixture of 17 (2.40 g, 5.10 mmol) and Pd/C (10% (wt/wt) on activated carbon, 240 mg) in methanol (50 ml) under H 2 (1 atm) at room temperature for 2 h.
25|
36| Filter through Celite. Concentrate the filtrate to a white wax and dissolve it in dioxane (20 ml) and H 2 O (20 ml).
37|
Add NaHCO 3 (0.94 g, 11.2 mmol) and Fmoc-OSu (1.89 g, 5.61 mmol) and stir the mixture at room temperature for 12 h.
38|
Remove dioxane and wash the remaining aqueous phase with diethylether (2 × 50 ml).
39|
Discard the combined diethylether layers and acidify the aqueous phase to pH 4 with 1 N HCl.
40| Extract with ethyl acetate (2 × 100 ml), and dry the combined ethyl acetate layer over Na 2 SO 4 , filter and remove solvent. . 7 ).
42|
Place the resin into a Pierce disposable plastic column.
43| Add 5 ml of DMF, cap the column, place it on a tube shaker and agitate for 20 min to swell the resin.
44|
Attach the column to a vacuum manifold and wash the resin with DMF (3 × 5 ml). Remove the column from the vacuum. 62| Place Fmoc-Glu(OtBu)-OH (212.8 mg, 0.5 mmol), 0.5 mmol PyBroP (233.1 mg, 0.5 mmol) and 3 ml of DMF in the column and agitate it on the shaker for 4 h.
63| Repeat
Step 44.
64| Repeat
Step 62 and then Steps 44-46 to yield 26.
65|
Repeat Steps 50 and 51 to give 27.
66|
Place Fmoc-5-Ava-OH (169.7 mg, 0.5 mmol), HOBT (67.6 mg, 0.5 mmol), DIC (63.1 mg, 0.5 mmol), DIPEA (87 µl, 0.5 mmol) and 3 ml of DMF in the column and agitate it on the shaker for 2 h.
67| Repeat Steps 44-46.
68| Place FITC (194.7 mg, 0.5 mmol), DIPEA (87 µl, 0.5 mmol) and 3 ml of DMF in the column and agitate it on the shaker for 4 h.  crItIcal step Run the FITC coupling reaction in the dark.
69|
Attach the column to a vacuum manifold and wash the resin with DMF (3 × 5 ml), methanol (3 × 5 ml), CH 2 Cl 2 (3 × 5 ml) and diethylether (3 × 5 ml). Remove the column from the vacuum manifold.
70| Dry under high vacuum for 4 h to yield 28.
71|
Cleave the resultant resin by adding into the column a mixture of TFA/H 2 O/triisopropylsilane (5.0 ml, 9:5:5); agitate it on the shaker for 2 h.
72|
Attach the column to a vacuum manifold and clean Erlenmeyer flask. Collect the filtrate and wash the resin with TFA (3 × 5 ml).
73|
Concentrate the filtrate using a rotary evaporator, precipitate the crude with diethylether and remove the solvent.
74|
Dissolve the resulting solid in 50% (vol/vol) aqueous acetonitrile (5 ml) and purify by preparative HPLC to yield 8d as described in the EQUIPMENT SETUP.  crItIcal step Aqueous acetonitrile contains 0.1% (vol/vol) TFA.  pause poInt The resultant peptide can be stored for an extended period at − 20 °C.
oxime-based library diversification from aminooxy 1 • tIMInG 24 h 75| Mix a solution of 1 (24 mM in DMSO, 30 µl), aldehyde (24 mM in DMSO, 30 µl) and acetic acid (48 mM in DMSO, 30 µl) in a 1.5-ml Sarstedt reaction tube and screw on the cap.
76|
Agitate the mixture gently for 24 h at room temperature.
77|
Use the resultant oxime solution 3 (8 mM in DMSO, 90 µl) directly for inhibition assay.  pause poInt The oxime solution can be stored extended long periods at a temperature of 2-8 °C.
oxime-based library diversification from aminooxy 8d • tIMInG 24 h 78| Mix a solution of 8d (15 mM in DMSO, 10 µl), aldehyde (15 mM in DMSO, 10 µl) and acetic acid (70 mM in DMSO, 10 µl) in a 1.5-ml Sarstedt reaction tube and screw on the cap.
79|
Agitate the mixture gently for 24 h at room temperature.  pause poInt Perform HPLC analysis on random oxime products to examine completion of reaction. Products typically show >90% purity.
80|
Use the resultant oxime solution 9 (5 mM in DMSO, 45 µl) directly for inhibition assays.  pause poInt The oxime solution can be stored for extended periods at a temperature of − 20 °C. 86| Place 12 micro test tubes (1.0-ml Titertube) in the second row of the rack.
87|
Use the above dilution process for a second screen (wells E1-H12).
? troublesHootInG Troubleshooting advice can be found in table 3.
• In situ synthesis of inhibitor 3. Purity = 94% (Fig. 10a, left) . Retention time: 19.303 min (Fig. 10a, left) 
